GlassScriptPrepare for your visit
George Karamigios
Cerritos, CA · NPI 1962466573
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$6,141.50
in general payments reported to CMS, 2019-2025 · $436 in 2025
The $436 reported for 2025 was more than what 76% of providers received nationally.
Who reported paying
General payments only, top 6 by amount.
- Janssen Pharmaceuticals, INC $2,151.21
- Teva Pharmaceuticals USA, INC. $1,188.44
- Otsuka America Pharmaceutical, INC. $662.19
- Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $412.94
- Allergan, INC. $378.15
- Neurocrine Biosciences, INC. $288.98
Drugs and devices associated with these payments
Uzedy Caplyta Igalmi Invega Sustenna Invega Trinza Cobenfy Rexulti Perseris Spravato Camzyos Abilify Asimtufii Orencia
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw George Karamigios listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/361040/george-karamigios